4.7 Article

Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study

期刊

SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41598-021-91823-x

关键词

-

向作者/读者索取更多资源

The study evaluated the impact of surgery on the survival and prognosis of patients with multifocal intrahepatic cholangiocarcinoma, finding that patients who underwent surgery had longer median survival times and significantly higher 5-year survival rates compared to those who did not undergo surgery.
The purpose of our study was to evaluate the effect of surgery on the survival and prognosis of patients with multifocal intrahepatic cholangiocarcinoma (ICCA). Patients with multifocal ICCA were selected from the SEER (Surveillance, Epidemiology, and End Results) database between 2010 and 2016. Kaplan-Meier analyses and log-rank tests were used to evaluate the difference in survival between the surgery group and the non-surgery group. We applied the Cox proportional hazards regression model to identify prognostic factors of overall survival (OS) and cancer-specific survival (CSS). In total, 580 patients were enrolled in our study, including 151 patients who underwent surgery and 429 patients who did not. The median survival time of surgical patients was longer than non-surgical patients (OS: 25 months vs. 8 months, p<0.001; CSS: 40 months vs. 25 months, p<0.001). Similarly, the 5-year survival rate in the surgery group was significantly higher than those in the non-surgery group (5-year OS rate: 12.91% vs. 0%; p<0.001; 5-year CSS rate:26.91% vs. 0%; p<0.001). Multivariate Cox analysis showed that the OS (HR:0.299, 95% CI: 0.229-0.390, p<0.001) and CSS (HR:0.305, 95% CI:0.222-0.419, p<0.001) of patients undergoing surgical resection were significantly improved. Meanwhile, after propensity score matching (PSM) of the original data, we come to the same conclusion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据